Business Context and Reporting Period
Daré Bioscience, Inc. (DARE) filed a Current Report on Form 8-K dated December 21, 2023. The filing discloses the entry into a Royalty Interest Financing Agreement with United in Endeavour, LLC ("United") to secure funding for the Company's operations.
Key Financial Metrics and Transaction Details
The transaction involves a royalty financing structure rather than traditional revenue or debt metrics. Key financial terms include:
- Initial Funding: The Company received an initial payment of $5 million on the Effective Date.
- Discretionary Funding: The Company may elect to receive up to an additional $7 million in supplemental payments between January 1, 2024, and December 31, 2026, for a potential total of $12 million.
- Repayment Obligation: The Company must pay United until the investor achieves a 12% internal rate of return (IRR) on the total invested amount (the "Hard Cap").
- Equity Issuance: The Company issued an initial warrant to purchase 5,000,000 shares of common stock at an exercise price of $0.3467 per share. Up to 7,000,000 additional warrants may be issued based on supplemental funding.
Material Changes and Payment Structure
The agreement establishes a tiered royalty payment schedule based on net sales and milestone payments from the Company's product, XACIATO, sold by Organon:
- 2023–2025: 50% of Net Royalty Payments.
- 2026–2029: 75% of Net Royalty Payments.
- Milestone Payments: 10% of net milestone payments through December 31, 2029.
- Extension: If the Hard Cap is not met by December 31, 2029, additional payments are required through 2034. If not met by 2035 and the Company has sufficient assets, quarterly payments will be made over a two-year term to satisfy the IRR.
The filing text does not provide specific revenue, profit, cash flow, or existing debt figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Outlook, Risks, and Management Commentary
Call Option: The Company retains the right, but not the obligation, to repurchase the royalty interest from United at any time for a price equal to the Hard Cap calculated as of the exercise date.
Warrant Terms: Warrants are exercisable for five years. They include customary anti-dilution adjustments and allow for cashless exercise if no effective registration statement is available.
Risks and Contingencies: The obligation to make payments is contingent upon the generation of royalty and milestone payments from XACIATO sales. However, the agreement includes a provision requiring payments from other sources of assets or income if the Hard Cap is not met by 2035 and the Company has sufficient resources.
Investor Verification Checklist
- Verify the current sales performance and royalty generation of XACIATO to assess the immediate cash flow impact of the 50% royalty payment obligation.
- Confirm the Company's intention and ability to exercise the discretionary option for the additional $7 million funding.
- Review the dilution impact of the 5,000,000 initial warrants and potential 7,000,000 additional warrants at the $0.3467 exercise price.
- Monitor the Company's cash reserves to determine if the "other sources of assets" clause could be triggered if XACIATO royalties are insufficient to meet the Hard Cap by 2035.